Andrea Denicoff

5.2k total citations
69 papers, 1.5k citations indexed

About

Andrea Denicoff is a scholar working on Oncology, Economics and Econometrics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andrea Denicoff has authored 69 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 28 papers in Economics and Econometrics and 26 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andrea Denicoff's work include Ethics in Clinical Research (21 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Economic and Financial Impacts of Cancer (15 papers). Andrea Denicoff is often cited by papers focused on Ethics in Clinical Research (21 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Economic and Financial Impacts of Cancer (15 papers). Andrea Denicoff collaborates with scholars based in United States, Malaysia and Switzerland. Andrea Denicoff's co-authors include Kenneth H. Cowan, Marianne Noone, Bryce B. Reeve, Ann M. O’Mara, Lori M. Minasian, Stacey L. Berg, Frank M. Balis, Ethan Basch, Sandra A. Mitchell and Deborah Schrag and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Andrea Denicoff

67 papers receiving 1.5k citations

Peers

Countries citing papers authored by Andrea Denicoff

Since Specialization

Citations

This map shows the geographic impact of Andrea Denicoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Denicoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Denicoff more than expected).

Fields of papers citing papers by Andrea Denicoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Denicoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Denicoff. The network helps show where Andrea Denicoff may publish in the future.

Co-authorship network of co-authors of Andrea Denicoff

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Denicoff. A scholar is included among the top collaborators of Andrea Denicoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Denicoff. Andrea Denicoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Streamlining the conduct of cancer clinical trials: new standard data collection practices for National Cancer Institute late-phase clinical studies 2024 ·JNCI Journal of the National Cancer Institute ·Sheila A. Prindiville, Sumithra J. Mandrekar, Neal J. Meropol, Andrea Denicoff, (unknown), Judith A. Hautala, James H. Doroshow	1
2	COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS) 2023 ·JNCI Journal of the National Cancer Institute ·Ana F. Best, (unknown), Jessica Li, (unknown), Andrea Denicoff, (unknown), Larry Rubinstein, Jeremy L. Warner, Brian I. Rini, Larissa A. Korde	4
3	Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials 2022 ·JNCI Journal of the National Cancer Institute ·Andrea Denicoff, S. Percy Ivy, (unknown), Jinxiu Zhao, (unknown), Margaret Mooney, Richard F. Little	14
4	National Cancer Institute: Restructuring to Support the Clinical Trials of the Future 2020 ·Seminars in Oncology Nursing ·Marjorie J. Good, Kathleen M. Castro, Andrea Denicoff, Shanda Finnigan, (unknown), Diane St. Germain	7
5	The National Cancer Institute and Department of Veterans Affairs Interagency Group to Accelerate Trials Enrollment (NAVIGATE): A federal collaboration to improve cancer care 2019 ·Seminars in Oncology ·Sara Schiller, Colleen Shannon, Mary T. Brophy, Andrea Denicoff, Marjorie J. Good, Sheila A. Prindiville, Grant D. Huang	5
6	Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute 2017 ·Journal of Oncology Practice ·Connie M. Szczepanek, Patricia A. Hurley, Marjorie J. Good, Andrea Denicoff, (unknown), (unknown), (unknown)	5
7	Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign 2017 ·Journal of Health Communication ·Holly A. Massett, David M. Dilts, Robert S. Bailey, Jennifer Berktold, Rebecca Ledsky, Nancy Atkinson, (unknown), Andrea Denicoff, (unknown), (unknown), (unknown), (unknown), Lenora Johnson	20
8	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 2016 ·Health and Quality of Life Outcomes ·Antonia V. Bennett, Amylou C. Dueck, Sandra A. Mitchell, Tito R. Mendoza, Bryce B. Reeve, Thomas M. Atkinson, Kathleen M. Castro, Andrea Denicoff, Lauren J. Rogak, Jay K. Harness, James D. Bearden, Donna Bryant, Robert D. Siegel, Deborah Schrag, Ethan Basch	94
9	Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 2013 ·Quality of Life Research ·(unknown), Jennifer L. Hay, Thomas M. Atkinson, Bryce B. Reeve, Sandra A. Mitchell, Tito R. Mendoza, Gordon Willis, Lori M. Minasian, Steven B. Clauser, Andrea Denicoff, Ann M. O’Mara, Alice Chen, Antonia V. Bennett, Diane Β. Paul, Joshua J. Gagne, Lauren J. Rogak, Laura Sit, Vish Viswanath, Deborah Schrag, Ethan Basch	121
10	Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). 2012 ·Journal of Clinical Oncology ·Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell, Bryce B. Reeve, Kathleen M. Castro, Andrea Denicoff, Ann M. O’Mara, Lauren J. Rogak, Steven B. Clauser, Donna Bryant, Theresa A. Gillis, James D. Bearden, Robert D. Siegel, Jay K. Harness, Diane Β. Paul, Charles S. Cleeland, Jeff A. Sloan, Deborah Schrag, Lori M. Minasian, Ethan Basch	9
11	Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 2011 ·Translational Behavioral Medicine ·Deborah Watkins Bruner, Laura J. Hanisch, Bryce B. Reeve, Andy Trotti, Deborah Schrag, Laura Sit, Tito R. Mendoza, Lori M. Minasian, Ann M. O’Mara, Andrea Denicoff, Julia H. Rowland, Michael Montello, Cindy Geoghegan, Amy P. Abernethy, Steven B. Clauser, Kathleen M. Castro, Sandra A. Mitchell, Laurie B. Burke, Ann Marie Trentacosti, Ethan Basch	64
12	Health-Related Quality of Life and Symptom Management Research Sponsored by the National Cancer Institute 2007 ·Journal of Clinical Oncology ·Lori M. Minasian, Ann M. O’Mara, Bryce B. Reeve, Andrea Denicoff, Joseph Kelaghan, Julia H. Rowland, Edward L. Trimble	39
13	Tamoxifen and fenretinide in women with metastatic breast cancer 1999 ·Breast Cancer Research and Treatment ·J. Zujewski, Lee H. Pai, Lalage M. Wakefield, Ruthann M. Giusti, F. Andrew Dorr, (unknown), Rafael C. Caruso, (unknown), Laurie Goodman, Maria J. Merino, (unknown), (unknown), Andrea Denicoff, David Venzon, Kenneth H. Cowan, Joyce O’Shaughnessy	30
14	Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. 1996 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Kenneth H. Cowan, D. Solomon, Frederick P. Ognibene, Barry R. Goldspiel, Richard Chang, Marianne Noone, Andrea Denicoff, (unknown), (unknown), Patricia Fetsch, Stacey L. Berg, Frank M. Balis, David Venzon, Joyce O’Shaughnessy	61
15	Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. 1996 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Kenneth H. Cowan, Marianne Noone, Andrea Denicoff, David Köhler, Barry R. Goldspiel, (unknown), Mary S. McCabe, (unknown), Jo Anne Zujewski, J. O’Shaughnessy	26
16	A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer 1995 ·Cancer Chemotherapy and Pharmacology ·Susan E. Bates, Beverly Meadows, Barry R. Goldspiel, Andrea Denicoff, (unknown), Eben Tucker, Seth M. Steinberg, L J Elwood	21
17	Chemotherapy-Induced Changes in Uterine Volume 1995 ·Journal of Computer Assisted Tomography ·P Kolachana, Kenneth H. Cowan, Andrea Denicoff, Elizabeth C. Jones, Peter L. Choyke	1
18	Pharmacokinetics of Taxol and Doxorubicin Administered Alone and in Combination by Continuous 72-Hour Infusion 1994 ·JNCI Journal of the National Cancer Institute ·Stacey L. Berg, Kenneth H. Cowan, Frank M. Balis, Jason S. Fisherman, Andrea Denicoff, (unknown), DG Poplack, Joyce O’Shaughnessy	57
19	Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. 1993 ·Journal of Clinical Oncology ·Diane Savarese, Andrea Denicoff, Stacey L. Berg, (unknown), (unknown), Joyce O’Shaughnessy, C. Chow, (unknown), Frank M. Balis, David G. Poplack	9
20	Therapy off patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin 1992 ·Anti-Cancer Drugs ·Lee H. Pai, Sandra M. Swain, David Venzon, Eddie Reed, Miriam C. Poirier, Shalina Gupta-Burt, Andrea Denicoff, Carmen J. Allegra	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact